Lysogene announced the renewal of its Board of Directors. The Board of Directors, which met on September 15th, 2022, decided to co-opt Mrs. Céline Fantin and Mr. Michel Picot as Directors to replace Mr. Philippe Goupit and Mr. Mathieu Simon, who are leaving, for the remaining term of their mandates (i.e. until the Annual General Meeting (AGM) to be called in 2024 to approve the financial statements for the year ending December 31, 2023). These appointments will be submitted for ratification at the next AGM of Lysogene in 2023.Mr. Michel Picot and Ms. Céline Fantin were also appointed respectively Chairman and member of the Audit Committee of the Board of Directors.

Céline Fantin will bring a new contribution to Lysogene with her expertise in audit and transformation programs in the pharmaceutical industry. Michel Picot will also provide to Lysogene his extensive experience in financing and strategy. With the departure of Mr. David Schilansky, whose mandate expired at the General Meeting of June 24, 2022, the Board of Directors of Lysogene is now composed of 5 members, including 4 independent directors.